Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well the tablet re-formulation ended up being very costly from both a time and money perspective, so this pivot/re-formulation really better pay off with stellar p2 results. Hopefully we get the readout data prior to the end of Q2 2024. I still see this as a strong risk/reward setup, it’s just been the opportunity cost of having tied up the funds. Interest in the share price should pick up heading into Q1.
This board is a ghost town.
My take on thecurrent situation with Antibe:
With a current $25M CAD m/c I think the risk/reward setup here is about 20% risk for 300%+ reward leading up to the phase 2 acute otena readout by late 2023. Worthy of a on of due diligence since there’s been a lot of costlyhiccups with this company but the shares are currently trading as though none of the underlying fundamentals matter at all.
The company has more than enough cash to fund the ph2 trial. They have pivoted from chronic to the acute pain market which, while smaller annual peak sales, offers a far more de-risked pathway to positive ph2 readout results and inevitable commercialization/buyout post ph3. The IP reformulation also demonstrably helps de-risk the results with a more rapid onset and significantly reduced dosing regime. This could enable them, once funds allow, to go back to chronic otena for a ph3. But the sweet spot is here and now for those with funds and about one year of patience.
What I’ve learned with biotechs is know your company very well but as important, know the cycle of when time and money are on your side or when they’re against you. All in my opinion.
**Attention Accredited Investor and Shareholders**
Please feel free to tune in to hear directly from management in an exclusive Zoom presentation for accredited investors and shareholders. Company executives will be giving an overview of the story while discussing upcoming catalysts and answering live questions. Register using the link below:
https://www.eventbrite.com/e/antibe-therapeutics-inc-webinar-6222021-registration-159355880729?ref=enivtefor001&invite=MjA1MDk0NjcvZ3RvZGRtYXJrZXlAZ21haWwuY29tLzA%3D%0A&utm_source=eb_email&utm_medium=email&utm_campaign=inviteformalv2&utm_term=eventpage
FDA clearance a bit dated but opens up US for stage 3 trials. Pretty sweet imo.
Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain http://ca.finance.yahoo.com/news/antibe-therapeutics-receives-fda-clearance-110000132.html?soc_src=community&soc_trk=ma
Flying low under the USA radar.
https://antibethera.com/
I’m pretty sure not many have looked into the potential this one has.
Long and IMO of coarse.
Yeah, baby!
After a long time - company found a partner and some funding.
Hopefully now they can move forward and give good results.
The product is good and has big potential in US
Excellent news, kudos to Dan and his team on this. More partnerships to come. Load up at these levels, still way undervalued!
ATBPF one for 10 reverse split. **PPS closed at .30
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Not great seemingly
See how the Canadian up listing will treat the stock. Positive so far with announcement
386,782,798 added another million plus to the o/s
Interesting biotech that has almost no volume, compared to similar ones, maybe the volume is north of the border?
The Drug and potential is very interesting. On my radar now.
Will major news and whole lot volume to break and run big time.
And time line on the Phase III trial?
more added, outstanding now 385,516,301
they added +100 million shares since last year.
added 19 million shares since 3/30, is this another dilution pos
Heard the cc and Q&A
They were all very positive - all plan for next steps.
The phase 2/3 is good but with 12 week trial with 300+ patients and split into 2 phases - I think it is a long road and funding may be an issue.
Yeah, not sure if people were just expecting a blow up instantly, but with the current MC to the potential I think we should see some real growth and pops at in partnership and other milestone. This is a multi dollar stock.
wow, but continued doo-doo-ing in the stock - big volume
Everything positive from the CC. lots of details, i believe they will put the transcript up on the website. Timelines haven't changed. everything moving forward as planned on better than expected results.
great - pls let us know what you think
can’t make it - can anyone else?
Especially given the volume here two days of very heavy downward volume
Agree - I cannot see any update from company or someone on why such a bad reaction.
I thought the results were good
I sold 30k at .45 and got out, should have sold friday, better not complain as douled money and dont like the action, good news and fall ? im moving on!
happens often, investors buy the rumor/speculation, then sell the news.
good luck
The market is failing to price these results into the share price. Wasn’t expecting shares to go down on positive news. What was the market expecting here, FDA approval. Any guesses as to stock performance? This company is very undervalued for its stage of development and product pipeline.
Very good news Amatuer17.
Results out - they look very good as expected.
All 3 doses showed very good results and top 2 doses showed statistical significance . New registrational pivotal P2/3 trial being planned.
https://finance.yahoo.com/news/antibe-therapeutics-announces-positive-top-103000987.html
I expected a delay, just not that much. I have a feeling it will be 2-3 weeks and they wanted to be safe give themselves a buffer zone.
Great hire in Dr Stauffer as Chief Medical Officer. Shows management’s confidence in P2b.
Another 6 weeks, apparently.....
6 more weeks - well at least they have all the data and no impact on trial parameters.
https://finance.yahoo.com/news/antibe-therapeutics-updates-timing-top-103000962.html
Followers
|
15
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
330
|
Created
|
08/10/15
|
Type
|
Free
|
Moderators |
Antibe Therapeutics is pursuing a major advance in the safe and non-addictive treatment of pain and inflammation. Our drugs are designed to prevent the widespread and serious gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs (“NSAIDs”), today’s most widely used medicines for the relief of pain. The NSAID class of drugs includes prescription and over-the-counter (“OTC”) brands such as naproxen (Aleve), celecoxib (Celebrex), ibuprofen (Advil), and Aspirin.
Global NSAID sales exceed $11 billion annually, a significant market opportunity that could potentially be disrupted by Antibe’s H2S technology.
Now in Phase 2 human clinical trials, Antibe’s lead drug, ATB-346, targets mild-to-moderate pain and inflammation arising from a wide range of medical conditions. In March 2018, ATB-346 showed unequivocal superiority to naproxen in GI safety (2.5% versus 42.1% ulceration rate) in a Phase 2B double-blind clinical trial (see press release). This human proof-of-concept data replicated the results of our pre-clinical studies, and suggests Antibe has potentially surmounted the main barrier to the non-addictive control of pain and inflammation. If ATB-346 obtains regulatory approval, physicians and consumers will gain a radically safer alternative to today’s NSAIDs and to the multi-dimensional dangers of corticosteroids (used for inflammation) and opiates (used for pain).
Antibe has two other promising drug candidates in its pipeline: ATB-352, a potent pain-killer targeting the urgent global need for a safer, non-addictive analgesic for treating severe pain; and ATB-340, GI-safe derivative of aspirin for chronic prevention of cardiovascular disease and cancer chemoprevention.
Rooted in more than ten years of academic and proprietary research, Antibe’s patent-protected drug development technology enables the linking of an NSAID molecule to a hydrogen sulfide-releasing molecule. Notably, hydrogen sulfide (“H2S”) is endogenously produced and utilized throughout the body, serving as an anti-inflammatory agent and signaling molecule. Combined with an expanding scope of indications for NSAID use, the unique properties of hydrogen sulfide promise substantially improved medicines for pain and inflammation across the spectrum of human illness.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |